Balto is a drug discovery company pursuing the limitless potential of small molecule inhibitors and degraders of protein-protein interactions (PPIs) in cancer and other diseases. 

Leveraging our proprietary and transformative PPI disruption and degradation (PP2D) platform, we have discovered first-in-class small molecules that inhibit and degrade critical drivers in cancer.

Unlike PROTACs, small molecule PPI inhibitors isolated with our PP2D platform function as monovalent targeted protein degraders, which could represent a new class of therapeutics.

For more information on our platform or pipeline, please contact us.